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Introduction: Food allergy is a recognized health problem, but little has been reported on its cost for health
services. The EuroPrevall project was a European study investigating the patterns, prevalence and socio-economic
cost of food allergy. Aims: To investigate the health service cost for food-allergic Europeans and the relationship
between severity and cost of illness. Methods: Participants recruited through EuroPrevall studies in a case–control
study in four countries, and cases only in five countries, completed a validated economics questionnaire.
Individuals with possible food allergy were identified by clinical history, and those with food-specific immuno-
globulin E were defined as having probable allergy. Data on resource use were used to estimate total health care
costs of illness. Mean costs were compared in the case–control cohorts. Regression analysis was conducted on cases
from all 9 countries to assess impact of country, severity and age group. Results: Food-allergic individuals had
higher health care costs than controls. The mean annual cost of health care was international dollars (I$)2016 for
food-allergic adults and I$1089 for controls, a difference of I$927 (95% confidence interval I$324–I$1530). A similar
result was found for adults in each country, and for children, and was not sensitive to baseline demographic
differences. Cost was significantly related to severity of illness in cases in nine countries. Conclusions: Food allergy
is associated with higher health care costs. Severity of allergic symptoms is a key explanatory factor.
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
Introduction
Immunoglobulin E (IgE)-mediated food allergy has been identifiedas a public health problem in several European countries.1–3 IgE-
mediated food allergies are adverse responses to food caused by the
immune system mistakenly identifying proteins in foods as harmful
to the body, triggering an allergic response. The allergic response can
range from mild symptoms, such as rashes, to severe symptoms,
such as anaphylactic shock, which can be fatal. Population-based
data on food allergies are limited.3–7 Previous studies have shown
that while up to 35% of individuals report adverse reactions to
foods, the prevalence of IgE-mediated food allergies is much lower
when diagnosis is confirmed. Hospital admissions in the UK where
systemic allergic reactions, including food allergy, were coded as the
diagnosis increased between 1990 and 2001.8 Currently, the only
treatment is avoidance of the causative food(s), which can have
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unintended consequences, including childhood malnutrition.9 Even
where an allergic person consciously avoids specific foods, traces
may be consumed accidentally. For people who have a clinically
diagnosed allergy, a reaction may result in administration of
adrenaline, seeking further medical help, and sometimes admission
to hospital. A recent burden of illness study in the USA10 estimated
the national direct health care cost of food-allergic reactions treated
in the health system to be $300 million. However, there has been a
lack of information about the health service costs imposed by food
allergies in Europe.7,8,11,12
The economic impact of food allergy may be widespread, affecting
many sectors of society both directly and indirectly.12 Estimates of
costs associated with any illness depend on which decision maker’s
perspective is adopted. For health policy makers, understanding
more about the cost of the use of health services that arises from
food allergy is the first step toward planning access to appropriate,
efficient and effective services and preventive strategies in future.
A range of theoretical backgrounds and modelling approaches
have been used to study how and why people seek and use health
services,13 with use of health services depending on a variety of
factors common to different illnesses. These include availability of
services, patients’ estimation of need, cost and various demographic
factors. Such studies have also shown that while the majority of
relatively healthy people with chronic conditions use no health
services, the overall cost and use of services is most strongly
predicted by severity of illness.14 As a consequence of the
complexity of interacting factors, it has been suggested that cost-
of-illness studies should adopt a case–control approach.15
This article presents the findings of an economic study, which
offered an opportunity to assess, from the perspective of health
care commissioners, potential additional direct health care costs
for providing services to people with food allergy compared with
those with no adverse reactions to food, and to assess whether the
severity of adverse reactions to foods had any impact on these costs,
in cohorts of adults and school-aged children across Europe. The
economic study was carried out within a European Commission
Framework 6 Integrated Project, EuroPrevall, which aimed to
assess the prevalence, cost and basis of food allergy in Europe.
Methods
The protocols for the EuroPrevall epidemiologic studies are
described fully elsewhere.5,6 A flowchart of the integration of the
economic study is available in Supplementary Appendix 1. To
summarize, random samples of local populations of primary
school–aged children and working-age adults in defined catchment
areas around the capital cities of 12 European countries were
recruited into the EuroPrevall Project using locally relevant
sampling frames, such as General Practitioners’ patient lists, city
council registration databases, local health authority/hospital
databases and, for the child survey, primary schools.
Sampling was carried out in three stages in each centre. In Stage 1,
a short screening questionnaire was posted to a random sample of
3000 households in the population to recruit the adult sample, and
via primary schools to recruit a sample of 3000 children, to collect
information about adverse reactions to food and willingness to par-
ticipate in the study’s second stage. In Stage 2, a random sample of
adults (aged 20–54 years) and children (aged 7–11 years) responding
to the screening survey and agreeing to take part in Stage 2 were
invited to take part in the age-specific case–control studies; the cases
within Stage 2 were categorized as respondents with ‘possible food
allergy’. All respondents were invited to complete a detailed ques-
tionnaire about the potential risks and exposures to food allergens,
and to undergo a blood test to allow serological analysis to establish
patterns of sensitization and test for presence of specific IgE against
24 selected foods.5 Respondents with both positive IgE results and
reported symptoms of food allergy were categorized as respondents
with ‘probable food allergy’. A random sample of 30 respondents
with probable food allergy in each centre, with mild reactions to
foods, were invited to a full clinical evaluation that included
double-blind placebo controlled food challenge in Stage 3 of the
clinical study.
The economic data were collected from cases with possible food
allergy and controls identified in four of the eight EuroPrevall
centres (Greece, Iceland, Poland and Spain) and from cases with
probable food allergy in seven centres (Poland, Spain, Czech
Republic, France, Italy, The Netherlands and UK). Data collection
took place between January 2007 and July 2009. In the following
sections of the article, the respondents in the economic study will be
referred to either as cases with possible or probable food allergy or
controls.
The development of the Food Allergy Economic Questionnaire
(FA-ECOQ), used to collect the data for this study, is described
elsewhere.16 A copy of the English language version of the question-
naire is attached as Supplementary Appendix 3. A power calculation
based on data collected in the pilot studies in the development of the
FA-ECOQ suggested that a minimum sample of 100 cases and 100
controls would be needed to show a statistical difference in direct
health care costs.16
Respondents to the FA-ECOQ are asked how often in the previous
12 months did they (or the study child) visit family doctors or other
professionals; whether they had used an ambulance, had been
prescribed medication or had been admitted to hospital; and if so,
how many times and how many days they spent in hospital. For this
analysis, cases and controls were included in analyses only if they
had reported data on the relevant variables.
The data were analysed in two ways to meet the aims of this study.
First, data collected from participants in Stage 2 of the case–control
clinical study were analysed to assess any differences in health
resource use between cases with possible food allergy and controls.
Second, to assess whether the severity of symptoms had any impact
on the health care costs for allergic people in the two age ranges, the
data from cases with possible and probable food allergy were
analysed by four categories of severity (mild, mild to moderate,
moderate and severe), controlling for demographic characteristics.
Severity of symptoms in cases was classified into four categories
using the Mueller clinical severity grading scale.17 If mild symptoms
(e.g. skin rashes) were reported, severity was categorized as Grade 1;
gastrointestinal symptoms or angio-oedema were categorized as
Grade 2; respiratory symptoms were categorized as Grade 3. The
most severe category was Grade 4 and included reported cardiovas-
cular symptoms and anaphylactic shock. Each centre was granted
ethical approval to participate in the economic study from their local
research ethics committee.
Costs of reported health services used over the previous year by
each respondent in all participating countries were calculated using
unit costs of service derived from the WHO-CHOICE database.18
This database uses the I$ (also known as the Geary–Khamis dollar)
to estimate unit costs of services. The I$ is an average unit of cost
derived by adjusting exchange rates between the US dollar and the
local currency to compare values of different currencies based on
purchasing power parity and the average commodity prices within
each country. Further details of the method are presented in
Supplementary Appendix 2. The outcome measure was ‘cost of
healthcare use (in previous year)’. This was derived by counting
the number of primary and outpatient services visited, hospital
inpatient stays by number of days admitted, use of ambulances
and prescribed medicines as quantities of health care resource use.
The quantities were multiplied by the relevant unit costs and
summed to create the ‘cost of health care use’ variable.
To assess difference in health care resource costs, a t-test based on
log-transformed cost variables or the 2 test of the mean total cost of
health care use between cases with possible food allergy and controls
in each survey in each country was controlling for demographic
and social characteristics of households (household size and
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household income), gender of respondent, gender of person with
allergy, employment status (‘head’ of household) and final educa-
tional level of the respondent (this was measured as primary school,
secondary school, technical college or university degree levels of
education relevant for each country).
Analysis of the effects of severity in cases of allergy (including both
possible and probable diagnoses) included estimation of the impact
on costs of different levels of severity (tests of means based on t-test
and analysis of variance based on log-transformed cost variable).
Linear regression analysis was applied, including three variables:
the two age groups surveyed (adults aged 20–54 years, children
aged 7–11 years), country and severity. This aimed to assess
whether there were significant effects of these variables on
combined health care costs. The reference groups for the
regression analysis were the following: for adult–child comparison,
‘adults with food allergy’; for the country comparison, ‘Poland’; and
for severity comparisons, ‘mild symptoms.’
Results
Study participants
Overall, 1411 participants in Stage 2 of the clinical study completed
an FA-ECOQ: 674 completed the adult FA-ECOQ, and 737
completed the parent FA-ECOQ on behalf of children aged 7–11
years (table 1). Additionally, 271 (165 adults and 106 parents of
study children) participants of Stage 3 of the clinical study
completed an FA-ECOQ (table 2).
Table 3 shows significant difference between cases and controls in
characteristics of respondents to both the adult and child surveys. In
the adult survey, a higher percentage of respondents were male in-
dividuals in the case group compared with the control group.
Children with possible or probable food allergies, in this survey,
lived in smaller households, with younger children and lower
incomes than those in the control group.
Response rates varied between centres and between cases and
controls, ranging between 19% of controls in the Greek child
survey and a maximum of 90% for the Spanish child survey.
Costs associated with possible food allergy:
case–control comparison
Table 4 presents the average number of visits to health professionals
for respondents from all participating countries in the year before
the survey, and for each participating country separately. The
aggregate analysis shows there is a significant difference in health
care resource use reported by those with ‘possible’ food allergies
compared with controls. Adults with ‘possible’ food allergy visited
health professionals, on average, 11.17 (SD = 16.14) times per year
compared with 7.11(SD = 12.80) visits per year reported by controls.
Children with ‘possible’ food allergy visited health professionals
10.75 times per year (SD = 13.23) compared with 6.56 (SD = 9.78)
visits per year reported by controls. Within Spain and Poland,
numbers of visits to health professionals are significantly higher
for adults and children with possible food allergy compared with
controls, respectively. Differences between the number of visits to
health professionals by adults and children with possible food allergy
and that by controls in Greece and Iceland do not reach conven-
tional levels of significance for ‘within country’ statistical tests. There
was no evidence of any heterogeneity of the difference between cases
and controls in the adult survey (P = 0.6117). There was evidence of
heterogeneity in the child survey (P = 0.0373), although none of the
individual two-country comparisons was significant. The difference
between cases and controls remained when adjusted for potential
confounders.
Table 5 shows that there was a significant difference in the
number of days spent in hospital in the previous year for both
adults and children with possible food allergies compared with
controls. Adults with food allergies spent a mean of 1.39 days in
hospital each year (SD = 7.43) compared with 0.46 (SD = 2.42) days
spent in hospital by controls. For children, those with possible food
allergies spent 0.75 (SD = 3.04) days in hospital compared with 0.40
(SD = 2.77) days spent in hospital by controls. There was no
evidence of any heterogeneity of the difference between cases and
controls in the adult (P = 0.8557) or the child (P = 0.2246) surveys.
The difference between cases and controls remained when adjusted
for potential confounders.
Table 3 Baseline characteristics of case and control respondents in the adult and child Food Allergy Survey [mean (SD)]
Baseline characteristics Adult Parent
n Cases n Controls P-value n Cases n Controls P-value
Total household members 215 2.98 (1.26) 429 3.04 (1.26) 0.4936 260 3.76 (1.01) 459 4.00 (1.15) 0.0044*
Household income 207 3264 (2055) 416 3455 (3216) 0.4348 254 3106 (2146) 439 3928 (4855) 0.0108*
Age 187 38.55 (10.75) 425 39.15 (10.05) 0.5058 231 9.10 (3.98) 411 10.16 (2.22) <0.001*
Gender (male/female) 193 70/123 430 198/232 0.023* 244 45/199 437 82/355 0.918
*Significant.
Table 1 Number of respondents or parents of study children with or
without possible food allergy completing FA-ECOQ
Country Number of respondents
Adulta Parentb
Case Control Case Control
Greece 27 9 21 28
Iceland 13 14 15 31
Poland 92 232 153 170
Spain 93 194 81 238
Total 225 449 270 467
a: Adults aged between 20 and 54 years.
b: Of children aged between 7 and 11 years.
Table 2 Number of respondents or parents of study children with
probable food allergy completing FA-ECOQ
Country Number of respondentsa
Adultb Parentc
Czech Republic 4 17
France 6 5
Italy 56 –
Netherlands 67 72
UK 32 12
Total 165 106
a: Cases only—no controls in this analysis.
b: Adults aged between 20 and 54 years.
c: Of children aged between 7 and 11 years.
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Tables 4 and 5 also show that there are absolute differences
between those with possible food allergy and controls in levels of
service use between countries, with higher service use overall by
adults in the Poland and the lowest service use in Greece. These
differences in service use are reflected in the level of costs of
health care use in different countries (table 6).
There are significantly higher costs of providing health services for
adults and children with possible food allergy compared with
controls for the whole sample. Overall, the mean cost of providing
health care to adults with possible food allergy is I$2016 compared
with I$1089 for controls, a difference of I$927 (95% confidence
interval based on untransformed data of I$324–I$1530). For
children aged 7–11 years, the costs are I$2197 for those with
possible food allergy compared with I$863 for controls, a
difference of I$1334 (95% confidence interval based on untrans-
formed data of I$729–I$1939). There was no evidence of any het-
erogeneity of the difference between cases and controls in the adult
survey (P = 0.3736) or the parent survey (P = 0.1061). The difference
between cases and controls remained when adjusted for potential
confounders.
Severity of reported allergy and health care costs
The mean average yearly cost of health care for 766 cases of possible
and probable food allergy in the nine participating centres was
I$1778. Table 7 shows that there is a significant gradient in costs
associated with severity of food allergy (as defined by reported
presence of specific clinical events and symptoms). There is
evidence that the cost of health services for those with moderate
food allergy (category 3) is likely to be 68% higher than for those
with the mildest symptoms of food allergy. The cost of health
services for those with severe food allergy (category 4) is predicted
to be twice that of those with mild food allergy. These differences are
significant at the 99% level of confidence, with P 0.0009. There is
also evidence that there are country-specific effects on the cost of
health care. There was no significant difference in the costs of health
services for children and adults.
Discussion
This survey indicates that both working-age adults and primary
school children with possible food allergy (identified as having
defined symptoms of food allergy) use more health services than
those without food allergy; therefore, the costs of providing health
services for people with food allergies is likely to be higher than the
cost of providing health service to people without food allergy
within these age-specific groups.
This finding was not sensitive to baseline differences in household
characteristics between the cases and controls. The result holds in all
Table 4 Health care resource use by country and study participation [mean (SD)]: health care contacts
Country Adult Parent
n Case n Control P-valuea n Case n Control P-valuea
Greece 27 1.81 (2.33) 9 1.14 (1.01) 0.693 18 3.01 (2.99) 26 2.32 (2.69) 0.521
Iceland 13 20.45 (27.27) 14 9.64 (14.68) 0.405 14 6.03 (7.27) 30 5.54 (11.15) 0.376
Poland 91 10.56 (12.14) 226 6.33 (11.47) <0.001* 149 12.16 (15.52) 167 9.59 (13.34) 0.022*
Spain 93 13.19 (18.62) 194 8.12 (14.27) 0.007* 81 10.69 (9.68) 238 5.02(5.81) <0.001*
Total 224 11.17 (16.14) 443 7.11 (12.80) <0.001* 262 10.75 (13.23) 461 6.56 (9.78) <0.001*
a: Test of log mean difference is >0 based on a linear regression model with log contacts +0.5 to allow for zero contacts.
*Significant.
Table 6 Health sector costs (I$2007 prices) for people with possible food allergy compared with controls in each country [mean (SD)]
Country Adult Parent
n Case I$ n Control I$ P-valuea n Case I$ n ControlI$ P-valuea
Greece 27 391 (583) 9 183 (265) 0.525 21 306 (360) 28 180 (234) 0.926
Iceland 13 1429 (2280) 14 554 (1073) 0.508 15 310 (432) 31 402 (937) 0.524
Poland 92 3318 (7986) 232 1504 (3171) <0.001 153 3074 (7043) 170 1715 (3475) 0.008*
Spain 93 1281 (2279) 194 673 (1100) 0.078 81 1379 (3876) 238 394 (1349) <0.001*
Total 225 2016 (5443) 449 1089 (2435) <0.001 270 2197 (5799) 467 863 (2405) <0.001*
a: Test of log mean difference based on a linear regression model with log contacts +0.5 to allow for zero inpatient days.
*Significant.
Table 5 Health care resource use by country and study participation [mean (SD)]: hospital days
Country Adult Parent
n Case n Control P-valuea n Case n Control P-valuea
Greece 19 0.32 (1.16) 6 0.50 (1.22) 0.268 16 0.81 (1.94) 24 0.13 (0.61) 0.082
Iceland 11 0.36 (1.21) 14 0.00 (0.00) 0.268 14 0.00 (0.00) 30 0.20 (0.76) 0.260
Poland 91 2.07 (9.12) 224 0.79 (3.32) 0.192 150 0.98 (3.81) 162 1.01 (4.55) 0.450
Spain 93 1.08 (6.70) 194 0.11 (0.54) 0.021* 81 0.42 (1.40) 238 0.03 (0.29) <0.001*
Total 214 1.39 (7.43) 438 0.46 (2.42) 0.020* 261 0.74 (3.04) 454 0.40 (2.77) 0.015*
a: Test of log mean difference based on a linear regression model with log contacts +0.5 to allow for zero inpatient days.
*Significant.
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countries participating in the case–control study, but the small
sample sizes in some countries meant there was insufficient power
to show a significant difference in each participating country.
Response bias is unlikely to have affected the findings, but should
be considered as a possibility in some settings. In the larger studies in
Poland and Spain, where local project managers were funded and
supported to implement the socio-economic study, the response
rates were excellent. Measurement of response was difficult in the
other centres, as records were not kept of how many questionnaires
were distributed. The research team sent packs of questionnaires for
use, and response rate calculation was based on the assumption that
all were handed out.
WHO-CHOICE unit costs were used to standardize costing meth-
odology across countries because it was impossible to obtain local
unit costs in all settings (see table A2.1 in Supplementary
Appendix 2). In four countries, we also had data from local
sources about unit costs of services used. A comparison of
the costs from different sources is shown in Supplementary
Appendix 2 (table A2.2). The costs estimated in this study are
lower than the estimates of population resource use and costs
published by the Organisation of Economic Cooperation and
Development (OECD).19 This may partly be due to the age distri-
bution of population in the EuroPrevall study, which included no
one aged >60 years. It is well reported that health care use is higher
for people in older age categories.20
Health policy depends on good information about prevalence
and severity of disease, appropriate care pathways and costs. We
have found only one recent report of health care cost of food
allergy,10 using administrative databases in the USA, to estimate
the cost of using services coded to food allergy–related illness.
Our study takes a different approach, but provides a basis for
modelling total direct health care costs in European countries,
even taking into account the small risk of recall error that
might be associated with the retrospective method of collecting
data about health resource use. However, as the economic study
was part of an integrated project, the methods for data collection
were constrained to what was feasible within that project.
EuroPrevall has described how people with food allergy use
services in different parts of Europe.4 This article provides data
that can be used to estimate direct health care costs of
programmes of care. Elsewhere, we report the estimated impacts
on direct, indirect and intangible costs of food allergies to indi-
viduals within households.21–25 Combined with evidence on effects
of options for allergy diagnosis and care on both health and
quality of life,26 the data reported here provide a key input to
estimating burden of illness and cost-effectiveness comparisons at
different levels in Europe.
This study has confirmed that suspected food allergy can have a
significant impact on health care costs in countries across Europe by
providing evidence that the cost of health care is significantly higher
for children and adults with food allergies than for those with no
food allergy, and that there is a positive relationship between the
severity of the symptoms of food allergy and the costs of providing
health care.
Supplementary data
Supplementary data are available at EURPUB online.
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Table 7 Effect of severity, country and whether adult or child on health care cost for people with probable food allergya
Covariate Coefficient Exponent of coefficient
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P-value*
Version (adult as baseline)
School-aged child 0.29 (0.04 to 0.61) 1.34 (0.96 to 1.85) 0.082
Country (Poland as baseline)b <0.0001*
Greece 1.17 (1.98 to 0.35) 0.31 (0.14 to 0.7)
Iceland 0.08 (1.16 to 1) 0.92 (0.31 to 2.73)
Spain 1.14 (0.5 to 1.78) 3.13 (1.66 to 5.92)
Czech Republic 0.42 (0.19 to 1.03) 1.53 (0.83 to 2.81)
France 1.02 (0.02 to 2.06) 2.77 (0.98 to 7.82)
Italy 0.53 (1.85 to 0.8) 0.59 (0.16,2.22)
Netherlands 0.19 (0.47 to 0.85) 1.21 (0.63 to 2.33)
UK 0.14 (0.92 to 0.63) 0.87 (0.4 to 1.88)
Severity (‘mild’ as baseline 0.0009*
2 0.02 (0.46 to 0.43) 0.98 (0.63 to 1.54)
3 0.52 (0.06 to 0.98) 1.68 (1.06 to 2.67)
4 0.81 (0.28 to 1.34) 2.25 (1.32 to 3.83)
a: Regression: log(cost) = version + country + severity.
b: Poland was chosen as the baseline because it was the country with the greatest number of cases; hence, the confidence
intervals for the two-country comparisons should be minimized.
	Significant.
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Key points
 Adults and children with suspected food allergies use more
health care resources than those with no suspicion of food
allergy.
 More severe symptoms of food allergy is associated with
higher costs of providing health care than is the case for
people with milder symptoms.
 Given this increased resource use, the diagnosis and
management of food allergies in the European countries
should be monitored and evaluated to ensure optimum
and cost-effective use of health resources.
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